Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas

[1]  S. Steinberg,et al.  Long-Term Safety and Efficacy of Selumetinib in Children with Neurofibromatosis Type 1 on a Phase 1/2 Trial for Inoperable Plexiform Neurofibromas. , 2023, Neuro-oncology.

[2]  C. Lázaro,et al.  ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1 , 2023, EClinicalMedicine.

[3]  T. Ågesen,et al.  Clinical Characteristics and Management of Children and Adults with Neurofibromatosis Type 1 and Plexiform Neurofibromas in Denmark: A Nationwide Study , 2022, Oncology and Therapy.

[4]  H. Koike,et al.  Surgical Treatment and Complications of Deep-Seated Nodular Plexiform Neurofibromas Associated with Neurofibromatosis Type 1 , 2022, Journal of clinical medicine.

[5]  M. Loh,et al.  MEK Inhibitors for Neurofibromatosis Type 1 Manifestations: Clinical Evidence and Consensus. , 2022, Neuro-oncology.

[6]  Michael Fisher,et al.  Management of Neurofibromatosis Type 1-Associated Plexiform Neurofibromas. , 2022, Neuro-oncology.

[7]  A. Hirbe,et al.  Plexiform neurofibroma: shedding light on the investigational agents in clinical trials , 2021, Expert opinion on investigational drugs.

[8]  S. Amin,et al.  Epidemiological and clinical burden associated with plexiform neurofibromas in pediatric neurofibromatosis type-1 (NF-1): a systematic literature review , 2021, Neurological Sciences.

[9]  M. Epelman,et al.  Pelvic plexiform neurofibroma during bowel/bladder dysfunction in an NF1 pediatric patient: A case report , 2021, Urology Case Reports.

[10]  Michael Fisher,et al.  Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation , 2021, Genetics in Medicine.

[11]  S. Sen,et al.  Natural History and Disease Burden of Neurofibromatosis Type 1 with Plexiform Neurofibromas: A Systematic Literature Review , 2021, Adolescent health, medicine and therapeutics.

[12]  Jiang Liu,et al.  FDA Approval Summary: Selumetinib for Plexiform Neurofibroma , 2021, Clinical Cancer Research.

[13]  B. Korf,et al.  NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Steven P. Angus,et al.  Cabozantinib for neurofibromatosis type 1–related plexiform neurofibromas: a phase 2 trial , 2021, Nature Medicine.

[15]  T. Lehky,et al.  Safe marginal resection of atypical neurofibromas in neurofibromatosis type 1. , 2020, Journal of neurosurgery.

[16]  S. Steinberg,et al.  Selumetinib in Children with Inoperable Plexiform Neurofibromas. , 2020, The New England journal of medicine.

[17]  K. Sarin,et al.  Phenotypic heterogeneity of neurofibromatosis type 1 in a large international registry , 2020, JCI insight.

[18]  B. Widemann,et al.  Current status of MEK inhibitors in the treatment of plexiform neurofibromas , 2020, Child's Nervous System.

[19]  T. Foiadelli,et al.  Advanced pharmacological therapies for neurofibromatosis type 1-related tumors , 2020, Acta bio-medica : Atenei Parmensis.

[20]  M. Krimmel,et al.  Surgical management of peripheral nerve sheath tumours in children, with special consideration of neurofibromatoses , 2020, Child's Nervous System.

[21]  G. Cerri,et al.  Surgery combined with embolization in the treatment of plexiform neurofibroma: Case report and literature review , 2020, JAAD case reports.

[22]  S. Steinberg,et al.  Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: Growth analysis of plexiform neurofibromas and distinct nodular lesions. , 2020, Neuro-oncology.

[23]  P. Wolkenstein,et al.  Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966 , 2020, Orphanet journal of rare diseases.

[24]  A. Chen,et al.  The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas. , 2020, Neuro-oncology advances.

[25]  A. Hirbe,et al.  Diagnosis and management of malignant peripheral nerve sheath tumors: Current practice and future perspectives , 2019, Neuro-oncology advances.

[26]  T. Rosenbaum,et al.  Trametinib Induces Neurofibroma Shrinkage and Enables Surgery , 2019, Neuropediatrics.

[27]  David T. Miller,et al.  Health Supervision for Children With Neurofibromatosis Type 1 , 2019, Pediatrics.

[28]  H. Terashi,et al.  Two cases of debulking surgery for lower limb diffuse plexiform neurofibroma with transcatheter arterial embolisation , 2019, International journal of surgery case reports.

[29]  S. Steinberg,et al.  Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1 , 2018, Neuro-oncology.

[30]  S. Peltonen,et al.  Prevalence of neurofibromatosis type 1 in the Finnish population , 2018, Genetics in Medicine.

[31]  C. Lázaro,et al.  2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis , 2018, American journal of medical genetics. Part A.

[32]  K. Fjermestad,et al.  Health Survey of Adults with Neurofibromatosis 1 Compared to Population Study Controls , 2018, Journal of Genetic Counseling.

[33]  R. Friedrich,et al.  Peripheral nerve sheath tumors of the upper extremity and hand in patients with neurofibromatosis type 1: topography of tumors and evaluation of surgical treatment in 62 patients , 2017, GMS Interdisciplinary plastic and reconstructive surgery DGPW.

[34]  Kimberly J. Johnson,et al.  Neurofibromatosis type 1 , 2017, Nature Reviews Disease Primers.

[35]  N. Ratner,et al.  Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. , 2016, The New England journal of medicine.

[36]  C. Marcus,et al.  Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1 , 2016, Neurology.

[37]  J. Blakeley,et al.  Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. , 2016, Neuro-oncology.

[38]  T. Vahlberg,et al.  Incidence and mortality of neurofibromatosis: a total population study in Finland. , 2015, The Journal of investigative dermatology.

[39]  M. Westphal,et al.  Growth behavior of plexiform neurofibromas after surgery , 2013, Genetics in Medicine.

[40]  T. Stinchcombe,et al.  KRAS mutation: should we test for it, and does it matter? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  G. Page,et al.  MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. , 2013, The Journal of clinical investigation.

[42]  C. Fox,et al.  Perioperative management of neurofibromatosis type 1. , 2012, The Ochsner journal.

[43]  Lisa J. Martin,et al.  Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1. , 2012, The Journal of pediatrics.

[44]  L. Kluwe,et al.  Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and associated clinical deficits. , 2011, The Journal of pediatrics.

[45]  F. Canavese,et al.  Resection of Plexiform Neurofibromas in Children With Neurofibromatosis Type 1 , 2011, Journal of pediatric orthopedics.

[46]  L. Mariani,et al.  Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: results of a pooled analysis from United States and European groups. , 2011, European journal of cancer.

[47]  Paul D. Smith,et al.  The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer , 2010, Clinical Cancer Research.

[48]  S. Huson,et al.  Birth incidence and prevalence of tumor‐prone syndromes: Estimates from a UK family genetic register service , 2010, American journal of medical genetics. Part A.

[49]  G. Hutchins,et al.  Nf1-Dependent Tumors Require a Microenvironment Containing Nf1 +/−- and c-kit-Dependent Bone Marrow , 2008, Cell.

[50]  D. Clapp,et al.  Nf1+/- mice have increased neointima formation via hyperactivation of a Gleevec sensitive molecular pathway. , 2008, Human molecular genetics.

[51]  Jan M Friedman,et al.  Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. , 2008, Neuro-oncology.

[52]  Paul D. Martin,et al.  AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models , 2007, Molecular Cancer Therapeutics.

[53]  S. Steinberg,et al.  NF1 plexiform neurofibroma growth rate by volumetric MRI , 2007, Neurology.

[54]  L. Parada,et al.  Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling. , 2006, Human molecular genetics.

[55]  J. Tonsgard.  Clinical manifestations and management of neurofibromatosis type 1. , 2006, Seminars in pediatric neurology.

[56]  I. Jacobs,et al.  Management of head and neck plexiform neurofibromas in pediatric patients with neurofibromatosis type 1. , 2005, Archives of otolaryngology--head & neck surgery.

[57]  D. Evans,et al.  Malignant peripheral nerve sheath tumours in neurofibromatosis 1 , 2002, Journal of medical genetics.

[58]  Q. Yang,et al.  Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. , 2001, American journal of human genetics.

[59]  T. Matsuishi,et al.  Mutation analysis of the methyl-CpG binding protein 2 gene (MECP2) in patients with Rett syndrome , 2000, Journal of medical genetics.

[60]  E. Zackai,et al.  Prognostic signs in the surgical management of plexiform neurofibroma: the Children's Hospital of Philadelphia experience, 1974-1994. , 1997, The Journal of pediatrics.

[61]  OUP accepted manuscript , 2022, Neuro-Oncology.

[62]  R. Friedrich,et al.  Surgery for Peripheral Nerve Sheath Tumours of the Buttocks, Legs and Feet in 90 Patients With Neurofibromatosis Type 1 , 2021, In Vivo.

[63]  B. Widemann,et al.  Orbital/Periorbital Plexiform Neurofibromas in Children with Neurofibromatosis Type 1: Multidisciplinary Recommendations for Care. , 2017, Ophthalmology.

[64]  Jan M Friedman,et al.  Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. , 2005, Archives of dermatology.

[65]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[66]  David A. Williams,et al.  Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/- mast cells. , 2003, The Journal of clinical investigation.